Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

September 30, 2026 updated by: Merck Sharp & Dohme LLC

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn:

  • About the safety and how well people tolerate of patritumab deruxtecan
  • How many people have the cancer respond (get smaller or go away) to treatment

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

180

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New South Wales
      • Sydney, New South Wales, Australia, 2145
        • Westmead Hospital ( Site 0100)
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Alfred Health ( Site 0102)
      • Melbourne, Victoria, Australia, 3084
        • Austin Health ( Site 0103)
    • Western Australia
      • Mount Pleasant, Western Australia, Australia, 6009
        • One Clinical Research ( Site 0104)
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • QEII Health Sciences Centre - Victoria General Site ( Site 0200)
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Research Institute - Odette Cancer Centre ( Site 0206)
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre ( Site 0202)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill ( Site 0300)
      • Santiago, Region M. de Santiago, Chile, 7500921
        • Fundacion Arturo Lopez Perez ( Site 0301)
      • Santiago, Region M. de Santiago, Chile, 7560908
        • Centro de Oncología de Precisión ( Site 0305)
      • Santiago, Region M. de Santiago, Chile, 7620002
        • Clínica UC San Carlos de Apoquindo ( Site 0302)
    • Anhui
      • Hefei, Anhui, China, 230088
        • The First Affiliated Hospital of Anhui Medical University ( Site 0405)
    • Fujian
      • Fuzhou, Fujian, China, 350014
        • Fujian Provincial Cancer Hospital ( Site 0408)
      • Xiamen, Fujian, China, 361015
        • Zhongshan Hospital Fudan University (Xiamen Branch) ( Site 0412)
    • Guangdong
      • Fuzhou, Guangdong, China, 510515
        • Southern Medical University Nanfang Hospital ( Site 0413)
      • Guangzhou, Guangdong, China, 510080
        • The First Affiliated Hospital, Sun Yat-sen University ( Site 0404)
    • Guangxi
      • Nanning, Guangxi, China, 530200
        • Affiliated Cancer Hospital of Guangxi Medical University ( Site 0411)
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Henan Cancer Hospital ( Site 0403)
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Zhongshan Hospital,Fudan University ( Site 0400)
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • First Hospital of Shanxi Medical University ( Site 0409)
    • Auvergne-Rhône-Alpes
      • Lyon, Auvergne-Rhône-Alpes, France, 69004
        • Hopital de la Croix Rousse ( Site 0502)
    • Hauts-de-Seine
      • Clichy, Hauts-de-Seine, France, 92110
        • Hopital Beaujon ( Site 0500)
    • Ille-et-Vilaine
      • Rennes, Ille-et-Vilaine, France, 35042
        • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0501)
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus ( Site 0603)
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center ( Site 0602)
      • Tel Aviv, Israel, 6423906
        • Sourasky Medical Center ( Site 0601)
      • Milan, Italy, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0700)
      • Milan, Italy, 20162
        • ASST Grande Ospedale Metropolitano Niguarda ( Site 0701)
      • Roma, Italy, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli ( Site 0702)
      • Auckland, New Zealand, 1023
        • Harbour Cancer & Wellness ( Site 0800)
      • Seoul, South Korea, 03722
        • Severance Hospital, Yonsei University Health System ( Site 0903)
      • Seoul, South Korea, 05505
        • Asan Medical Center ( Site 0902)
      • Seoul, South Korea, 06351
        • Samsung Medical Center ( Site 0901)
    • Seoul
      • Seodaemun-gu, Seoul, South Korea, 03080
        • Seoul National University Hospital ( Site 0900)
      • Barcelona, Spain, 08035
        • Hospital Universitari Vall d Hebron ( Site 1000)
      • Madrid, Spain, 28007
        • Hospital Universitario Gregorio Maranon ( Site 1002)
      • Madrid, Spain, 28040
        • Hospital Clinico San Carlos... ( Site 1003)
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spain, 33011
        • Hospital Central de Asturias ( Site 1001)
      • Geneva, Switzerland, 1211
        • Hopitaux Universitaires de Geneve HUG. ( Site 1102)
      • Zurich, Switzerland, 8091
        • Universitaetsspital Zuerich ( Site 1105)
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital-Clinical Trial Center ( Site 1502)
      • Taipei, Taiwan, 10002
        • National Taiwan University Hospital ( Site 1500)
      • Taipei, Taiwan, 112201
        • Taipei Veterans General Hospital ( Site 1501)
    • Bangkok
      • Bangkoknoi, Bangkok, Thailand, 10700
        • Faculty of Medicine Siriraj Hospital ( Site 1301)
      • Ratchathewi, Bangkok, Thailand, 10400
        • Ramathibodi Hospital ( Site 1302)
      • Adana, Turkey (Türkiye), 01370
        • Adana City Hospital ( Site 1404)
      • Ankara, Turkey (Türkiye), 06230
        • Hacettepe Universite Hastaneleri ( Site 1401)
    • Ankara
      • Yenimahalle, Ankara, Turkey (Türkiye), 06200
        • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1400)
    • İzmir
      • Balçova, İzmir, Turkey (Türkiye), 35340
        • Dokuz Eylul Universitesi Hastanesi ( Site 1402)
    • California
      • Santa Monica, California, United States, 90404
        • UCLA Hematology Oncology Santa Monica ( Site 1205)
    • Colorado
      • Aurora, Colorado, United States, 80045
        • University of Colorado Cancer Center ( Site 1200)
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20016
        • Sibley Memorial Hospital ( Site 1208)
    • Florida
      • Gainesville, Florida, United States, 32610
        • University of Florida ( Site 1202)
      • Miami Beach, Florida, United States, 33140
        • Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213)
    • Georgia
      • Marietta, Georgia, United States, 30060
        • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203)
    • Illinois
      • Chicago, Illinois, United States, 60637
        • University of Chicago Medical Center ( Site 1204)
    • Nevada
      • Reno, Nevada, United States, 89502
        • Renown Regional Medical Center ( Site 1221)
    • New York
      • Mineola, New York, United States, 11501
        • NYU Langone Hospital - Long Island ( Site 1230)
      • New York, New York, United States, 10016
        • Perlmutter NYU Cancer Center ( Site 1212)
    • Texas
      • Temple, Texas, United States, 76508
        • Scott & White Medical Center-Temple ( Site 1224)
    • Virginia
      • Roanoke, Virginia, United States, 24014
        • Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 1207)
    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • University of Wisconsin ( Site 1210)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has one of the following cancers:

    • Unresectable or metastatic colorectal cancer.
    • Advanced and/or unresectable biliary tract cancer (BTC)
    • Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
    • Locally advanced unresectable or metastatic gastroesophageal cancer
  • Has received prior therapy for the cancer.

  • Has recovered from any side effects due to previous cancer treatment

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
  • Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
  • Has evidence of any leptomeningeal disease
  • Has clinically significant corneal disease
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patritumab deruxtecan

Participants receive patritumab deruxtecan intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Administered via intravenous (IV) infusion

Other Names:
  • U3-1402
  • HER3-DXd
  • MK-1022

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Experiencing Dose-Limiting Toxicity (DLT) (Dose-Escalation Phase)
Time Frame: Up to 21 days

DLT will be defined as any drug-related adverse event observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next 21-day cycle. The number of participants in the dose-escalation phase who experience a DLT will be presented.

Up to 21 days
Number of Participants with One or More Adverse Events (AEs)
Time Frame: Up to approximately 44 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 44 months
Number of Participants who Discontinue Study Intervention Due to an AE
Time Frame: Up to approximately 44 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 44 months
Objective Response Rate (ORR)
Time Frame: Up to approximately 44 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 44 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of Response (DOR)
Time Frame: Up to approximately 44 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

Up to approximately 44 months
Progression Free Survival (PFS)
Time Frame: Up to approximately 44 months

PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 44 months
Overall Survival (OS)
Time Frame: Up to approximately 44 months

OS is the length of time from when the participant starts treatment until death from any cause.

Up to approximately 44 months
Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan
Time Frame: At designated time points (up to ~44 months)

Blood samples collected at protocol specific time points will be used to determine the Cmax of patritumab deruxtecan.

At designated time points (up to ~44 months)
Trough Concentration (Ctrough) of Patritumab Deruxtecan
Time Frame: At designated time points (up to ~44 months)

Blood samples collected at protocol specific time points will be used to determine the Ctrough of patritumab deruxtecan.

At designated time points (up to ~44 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Medical Director, Merck Sharp & Dohme LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 3, 2024

Primary Completion (Estimated)

December 7, 2028

Study Completion (Estimated)

December 7, 2028

Study Registration Dates

First Submitted

September 11, 2024

First Submitted That Met QC Criteria

September 11, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

October 2, 2026

Last Update Submitted That Met QC Criteria

September 30, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 1022-011
  • MK-1022-011 (Other Identifier: MSD)
  • U1111-1305-0677 (Registry Identifier: UTN)
  • 2024-512442-41-00 (Registry Identifier: EU CT)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe